Search Results

The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.

An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.

Irish Health Minister Jennifer Carroll MacNeill positions the €10 billion EU Biotech Act as a key priority for Ireland's Council Presidency, aiming to reverse the decline in clinical trials while balancing pharmaceutical incentives against patient access to affordable therapies.

The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines — a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

A massive wave of regulatory reform is sweeping the global pharma industry in 2026. From the EU's most significant legislative overhaul in decades to the FDA's sweeping Operation TrialBlazer, we break down what quality, manufacturing, and regulatory teams need to know to stay compliant.

An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.

An in-depth analysis of Eli Lilly’s massive manufacturing footprint in Limerick and Kinsale, highlighting local jobs, high-tech biologic drug production, and Ireland’s strategic position in the global biopharma supply chain.

A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.

The European Union's new General Pharmaceutical Legislation and the Critical Medicines Act have been finalized, representing the most significant overhaul of European medicines law in over two decades. Here is what global companies must know to adapt.

The European Commission has proposed the European Biotech Act to turbocharge the EU's health biotechnology sector, streamline regulations, and regain global competitiveness against the US and China.

Despite encouraging growth in clinical trial activity, patients in Ireland face an average wait of 801 days for access to rare disease medicines, prompting calls for urgent systemic reform.

With the US pushing for individual drug pricing deals and Germany slashing healthcare spending, the Beneluxa Initiative represents five European nations calling for a unified, coordinated approach to protect Europe's pharmaceutical innovation and access to medicines in 2026.

Cannabinoid APIs are transforming pharma with precise, plant-derived medicines, balancing sustainability, regulation, and innovation.